Clinical Supply Management Articles

1. Multispecific Trial Supply Stability Hinges On CDMO Agility 6/10/2025

   Naya's CEO describes the dynamics of producing a complex therapeutic for clinical trials on another continent, and how choice of CDMO plays heavily into that strategy.

2. A Road Map For Transitioning From A Research-Focused To Commercialization Mindset 6/3/2025

   As the timeline for commercialization closes in, it’s necessary to best position the organization for a successful launch. Where to start?

3. The Potential Impact Of U.S. Tariffs On The Biotech Sector: Manufacturing, Funding, And Clinical Trials 5/12/2025

   Syner-G Biopharma Group's Raymond Forslund, Ph.D., MBA explores how U.S. tariffs might affect biotech manufacturing, funding, and clinical research.

4. The 4 Technologies Poised To Transform The Pharmaceutical Supply Chain In 2025 And Beyond 12/2/2024

   These key technological advancements will significantly impact the pharma/biotech supply chain in 2025 and beyond. If you aren't implementing any of them yet, you may want to rethink your plans.

5. Sourcing Plasmid DNA From CDMOs Got More Challenging — Here's Why 11/19/2024

   The demand for plasmid DNA products is intrinsically linked to unique market conditions and funding environments. Here's what's driving them.

6. How Recce Is Delivering 5,000 Doses Per Week For Its Clinical Trials 10/25/2024

   Automation and the underlying chemistry of its R327 candidate have helped the antibiotic developer reach notably high production volumes.

7. Exploring Sanofi R&D's Batch Monitoring Initiative 10/23/2024

   The project established predictability during testing and release for the production of medicine to support clinical trials.

8. What's In The Leukopak Matters For Cell Therapy Manufacturing 10/11/2024

   Advanced cell-based therapies are impossible without high-quality leukopaks from high-quality donors.

9. When Should You Select Your Supply Partner? 9/19/2024

   In this part two, James Doherty, President and Chief Development Officer, provides readers with a window into the contracting strategy of Acumen Pharmaceuticals, a biotech developing a novel therapeutic for the treatment of Alzheimer’s disease (AD). Acumen has announced it entered a CDMO contract for both clinical and any future commercial supply.

10. If The CDMO Shoe Fits, Wear It Now 9/16/2024

    Acumen Pharmaceuticals, a clinical-stage biopharmaceutical developing a novel therapeutic for the treatment of Alzheimer’s, selected its manufacturing partner early on, and told the world about it. Chief Editor Louis Garguilo asked the chief development officer about that strategy.